Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468270 | 0.88 | CA9 (0.48) | IRAK4CA12CA9CA1CA2 | |
| SCHEMBL6467418 | 0.85 | IRAK4 (0.45) | IRAK4ITKPARP1HDAC1HDAC2 | |
| SCHEMBL6508306 | 0.85 | CA9 (0.54) | CA12CA9CA1CA2 | |
| SCHEMBL6499276 | 0.84 | KDM4E (0.43) | IRAK4CA12CA9CA1CA2 | |
| SCHEMBL6505306 | 0.83 | CA12 (0.42) | IRAK4CA12CA9CA1CA2 | |
| SCHEMBL6470265 | 0.82 | ITK (0.42) | IRAK4CA12CA9CA1CA2 | |
| SCHEMBL6507678 | 0.82 | IRAK4 (0.41) | IRAK4ITKPARP1HDAC1HDAC2 | |
| SCHEMBL6470394 | 0.82 | IRAK4 (0.42) | IRAK4ITKPARP1HDAC1HDAC2 | |
| SCHEMBL6467588 | 0.82 | ABCC9 (0.42) | IRAK4CA12CA9CA1CA2 | |
| SCHEMBL6469788 | 0.78 | KMT2A (0.46) | IRAK4CA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | IRAK4 27/4885CA12 3831/4885CA9 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.